CRISPR Therapeutics will present clinical data from its ongoing Phase 1/2 trial of zugocabtagene geleucel (zugo-cel) in patients with large B-cell lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting in December. The presentation will cover the allogeneic CAR-T cell therapy and its dose-dependent efficacy in this patient population.
The announcement follows the company’s third-quarter earnings report, which showed a wider-than-expected loss and strong revenue growth from its gene therapy Casgevy. Wells Fargo also lowered its price target on CRISPR shares to $70 from $75, citing model adjustments following the earnings release.